Stock comparison
Haemonetics
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 71B | UTHR |
| Benjamin Graham | 85A | 76B | HAE |
| Philip Fisher | 60C | 76B | UTHR |
| Peter Lynch | 54C | 62C | UTHR |
| Joel Greenblatt | 31F | 46D | UTHR |
| Charlie Munger | 54D | 64C | UTHR |
| Terry Smith | 55D | 64C | UTHR |
Side-by-side metrics
| Metric | HAE | UTHR |
|---|---|---|
| Market cap | $2.98B | $24.13B |
| P/E (TTM) | 24.8x | 19.2x |
| EV/EBIT | 14.1x | 15.2x |
| ROIC (TTM) | 8.37% | 18.81% |
| Gross margin | 55.74% | 86.58% |
| Net margin | 7.29% | 40.61% |
| Revenue CAGR 5y | 7.65% | 17.22% |
| EPS CAGR 5y | 24.62% | 29.84% |
| Debt / Equity | 1.5x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EV/EBIT14.1xvs 15.2x+7%
UTHR leads on
- Debt / Equity-vs 1.5x+100%
- Market cap$24.13Bvs $2.98B+88%
- Net margin40.61%vs 7.29%+82%
- Revenue CAGR 5y17.22%vs 7.65%+56%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.